Introduction
Sickle cell disease (SCD) is the consequence of homozygosity for a single amino acid change in the β-globin chain that results in structurally abnormal hemoglobin S, or by compound heterozygosity for hemoglobin S and another β-globin chain abnormality, typically hemoglobin C or β-thalassemia. In addition, α-thalassemia is a modifier of the clinical manifestations of SCD.
The sickle-cell gene, β-thalassemia and α-thalassemia are distributed widely throughout subSaharan Africa the Middle East and parts of the Indian subcontinent, all areas of high prevalence of malaria historically. This striking overlap in the historical distribution of malaria and hemoglobin S, β-thalassemia and α-thalassemia provides evidence that protection from malaria mortality is what provided a heterozygote advantage for these mutations to become prevalent in certain populations. Carrier rates for hemoglobin S range from 5% to 40% or more of the population in these areas (1) .
Sickle cell disease is among the most common monogenetic diseases worldwide (2) . It is estimated that 312,000 people with hemoglobin SS (Hb SS) are born each year throughout the world, with the majority of these births (236,000) in sub-Saharan Africa (3) . Based on the World Health Organization published global prevalence map of SCD and other data (http://www.who.int/genomics/public/Maphaemoglobin.pdf), about 20-25 million individuals world-wide have homozygous SCD; 12-15 million in sub-Saharan Africa, 5-10 million in India and about 3 million distributed in other parts of the world. Migration patterns have led to the distribution of the sickle cell genes into regions that are not endemic for malaria. About 8% of African Americans carry the sickle gene (4, 5) and the expected incidence of SCD at birth is 1 in 625 (6, 7) . Approximately 100,000 people with SCD live in the United States (8) .
Hemoglobin S polymerizes upon deoxygenation and this causes erythrocyte rigidity, sickling and early destruction. Vaso-occlusion and hemolysis related to these rigid and/or sickled cells lead to disease manifestations, including hemolytic anemia, severe pain episodes from bone marrow ischemia, central nervous system strokes, the acute chest syndrome, pulmonary hypertension, left-sided heart disease, bacteremia, leg ulcers, growth failure, priapism and damage to the spleen, kidneys, liver and bones (9) . The disease severity varies considerably among patients with SCD and even among those with Hb SS. While some patients have severe complications and die before the third decade, others may remain largely asymptomatic. For example, in an investigation of pain involving 3578 patients as a part of the Cooperative Study of Sickle Cell Disease (CSSCD), 5.2 % had 3-10 painful episodes requiring medical care per year while 39% had none (10) .
Prominent recognized factors that influence the severity of SCD include the genotype, for example Hb SS versus hemoglobin SC (Hb SC) versus hemoglobin Sβ-thalassemia (Hb Sβ-thalassemia), the coexistent presence of α-thalassemia, and the level of hemoglobin F (Hb F).
We will consider the geographic distribution of these factors and how they influence the pulmonary and cardiac complications of SCD. This paper does not represent a formal metaanalysis or a comprehensive review of the literature. Rather it provides selected examples of geographic variation and prevalences.
Distribution of sickle cell disease genotypes in patients of predominantly African origin in the Americas and the UK
The predominant genotypes that give rise to SCD include Hb SS, Hb SC, Hb Sβ + -thalassemia and Hb Sβ 0 -thalassemia. Other rare forms include hemoglobin SD and hemoglobin SE. Three recent large multicenter cohorts provide the distribution of these genotypes among SCD patients of predominantly African origin in the Americas and the UK (Table 1 ). In a crosssectional study conducted at three centers in Brazil, 773 children and adolescents 2-16 years of age were screened with transcranial Doppler ultrasound (11) . In the Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH) study conducted at four tertiary medical centers in the US, 720 individuals 3 to 20 years of age were screened with echocardiography as outpatients at steady-state (12) . In the Walk-PHaSST (treatment of Pulmonary Hypertension and Sickle cell disease with Sildenafil Therapy) study individuals ≥12 years with SCD were screened with echocardiography as outpatients at steady-state at nine US Centers and one UK Center, with 89.3% of the patients being over 20 years of age (13) . In these three cohorts, the proportion of Hb SS genotype ranged from 74-76%, of Hb SC from 18-24%, and of Hb Sβ-thalassemia from 1-6%.
Geographic variability of distribution of sickle cell disease genotypes outside the

Americas and UK
Given the fairly uniform distribution of sickle genotypes in the Americas and the UK, it is striking how different the distributions are in specific geographic areas where malaria is endemic (Table   2 ). Among three university hospital-based cohorts from Nigeria and Senegal, the proportion of Hb SS genotype ranged from 88-96%, of Hb SC from 4-12%, and Hb Sβ-thalassemia <1% (14) (15) (16) . In contrast, among 153 SCD individuals identified through screening programs in villages or schools in the area of Ouagadougou, Burkina Faso, 92% had the Hb SC genotype and 8% had the Hb SS (17) . The genotype distribution among 387 SCD patients diagnosed by performing hemoglobin electrophoresis in an urban hospital in Ouagadougou was 50% Hb SC and 50% Hb SS (18) , likely representing an increased likelihood for Hb SS patients to present to the hospital with problems requiring diagnosis and treatment. Further variation is shown in cohorts from Greece (19) and Chennai, India (20) , where the predominant genotype is Hb Sβ-thalassemia but Hb SS comprises 19-36% of the cohorts, and in a cohort from Andhra Pradesh, India (21) , where the predominant genotype is Hb SS but Hb Sβ-thalassemia makes up 31% of the cohort.
Geographic variability of α-thalassemia in sickle cell disease
The α-thalassemias are frequently encountered in malaria endemic regions of Southeast Asia, Africa, India, and the Middle East. The α-globin genes are duplicated on each copy of chromosome 16 for a total of four α-globin genes (αα/αα). Deletions (e.g. Migration patterns have led to the distribution of α-thalassemia deletion and non-deletion mutations in non-malaria endemic regions. In the general population of African Americans, the frequency of the (-α) chromosome is estimated at 0.16 and is similar to that observed in African
Brazilians (39, 40) . Among Hb SS patients from North and South America, the (-α) chromosome frequencies range from 0.12 to 0.23 (41) (42) (43) (44) .
Geographic variability of hemoglobin F in sickle cell disease
Fetal hemoglobin (HbF), which is composed of two α-hemoglobin subunits and two γ-hemoglobin subunits (α 2 γ 2 ), is the major hemoglobin produced during fetal development. The expression of Hb F starts early in development, peaks in mid-gestation, and by six months of age very little is expressed in most people. Fetal hemoglobin has a higher affinity for oxygen than hemoglobin A (Hb α 2 β 2 ) due to a decrease in its interaction with 2, 3-bisphosphoglycerate.
It is thought that this increase in oxygen affinity allows for better oxygen transfer across the placenta from the mother to fetus.
The suggestion that Hb F may be responsible for the lack of clinical symptoms in newborns with SCD, was first made by Watson (45) in 1948, who reported that the occurrence of clinical symptoms of SCD started with a decline in Hb F levels. Since then, it is now appreciated, that
Hb F is among the most important known modifiers of the clinical course of SCD (10) . Fetal hemoglobin is believed to decrease hemolysis, and therefore the many complications of SCD, since both fetal hemoglobin (α 2 γ 2 ) and the mixed hybrid hemoglobin tetramers that form (α 2 γβ s )
do not participate in the polymerization of the deoxy-sickle hemoglobin. (46) A wide range of Hb F expression has been observed among SCD patients from various parts of the world (47) . Many people from the Middle East and India co-inherited additional genetic mutations that allow for the persistence of Hb F production, so that as a population they appear to have less severe disease.
There are several haplotypes of the hemoglobin S gene that correlate with region of origin of the mutation and are associated with variation in the expression of Hb F (28, 48) . These include the Senegal, Saudi-Indian, Benin, and Bantu haplotypes (49 (64, 71) . The cause of acute chest syndrome is known in only about a third of cases and is related to pulmonary infections, pulmonary infarction and fat embolism (44, (72) (73) (74) . Acute chest syndrome seems to be associated with a personal or family history of asthma, increased inflammatory markers, and increased phospholipase A2 levels. A physician diagnosis of asthma has been associated with increased incidence of acute chest syndrome, pain, and early death (75) . In a cohort of 291 infants in the Cooperative Study of
Sickle Cell Disease who were prospectively followed for 11 years, acute chest syndrome was and asthma has also been a source of speculation, as has the role of nitric oxide. An increase in exhaled nitric oxide correlates with increased asthma severity, but NO bioavailability decreases with more severe hemolysis, higher plasma free hemoglobin levels, and higher TRV.
Oxygen desaturation has an independent association with left ventricular hypertrophy and diastolic dysfunction in patients with SCD (77) . TRV reflects systolic pulmonary artery pressure and right ventricular systolic pressure (78) . A TRV of > 3.0 m/sec in adults carries a substantial probability of finding mean pulmonary artery pressure > 25 mm Hg on right heart catheterization (79) and signifies an increased risk of early mortality (80) . The clinical significance of an elevated TRV in children is less well defined, although we have reported a decline in exercise capacity over two years of follow-up in children with a TRV > 2.6 m/sec (81). Plasma concentration of brain natriuretic peptide (BNP), which is concentrated in the heart and is believed to play an emergency defense against ventricular overload in disease states (82), serves as a diagnostic marker for heart failure and left ventricular dysfunction (83, 84) . Nterminal NT-proBNP is produced from proBNP cleavage (85) . Serum NT-proBNP concentration correlates with pulmonary artery pressure, right ventricular dysfunction (86) , and left ventricular diastolic dysfunction (87) . Elevated NT-proBNP predicts a group of patients with higher mortality (86, 88, 89) . (90), were higher in the patients with Hb SS, consistent with a greater propensity to red blood cell sickling and hemolysis. In terms of pulmonary complications, oxygen saturation <95% as determined by pulse oximetry, elevated TRV, and elevated NT-proBNP concentration were more common with the Hb SS genotype in both the PUSH and Walk-PHaSST cohorts.
History of acute chest syndrome did not differ significantly according to the three genotypes.
The contributions of LV volume overload and diastolic dysfunction to mild TRV elevations seen in pediatric patients with SCD are well described (91 There seems to be a decreased incidence of involvement of vital organs in SCD patients with alpha-thalassemia (97), and alpha-thalassemia appears to increase survival in certain populations (98) . The effect of alpha-thalassemia is not always beneficial, because some complications such as aseptic necrosis and retinal disease occur more frequently in patients with concurrent alpha-thalassemia (95, 99) . In individuals homozygous for the hemoglobin S mutation, α-thalassemia due to single or double α-globin gene deletions (96, 100, 101) is associated with higher hemoglobin concentrations and less hemolysis, blunted response to therapies aimed at increasing Hb F, and more frequent pain crises (27, 96, (100) (101) (102) (103) (104) (105) (106) .
The effects of co-inheriting α-thalassemia with SCD on pulmonary and cardiac complications have been less clear. There have been conflicting reports on risks for acute chest syndrome in Hb SS individuals with α-thalassemia with some but not all reporting fewer episodes of acute chest syndrome in patients with α-thalassemia (96, 107, 108) . Coinheritance of α-thalassemia has not been shown to be significantly associated with a TRV > 2.5 m/s in screened individuals with SCD including a subgroup analysis of Hb SS subjects (69). Table 4 depicts new analyses of the PUSH and Walk-PHaSST Hb SS patients for selected clinical manifestations according to α-thalassemia genotype. Hemoglobin concentrations were higher and LDH concentrations were lower in the patients with α-thalassemia (αα/α-or α-/α-) than those without (αα/αα), consistent with a protection from severe hemolysis and marked anemia by α-thalassemia. Among children in the PUSH cohort, number of severe pain episodes in the past year was more in the patients with α-thalassemia. In contrast, among predominantly adults in the Walk-PHaSST cohort, the number of pain episodes did not differ significantly according to the presence or absence of α-thalassemia. History of leg ulcers was lower with α-thalassemia in the Walk-PHaSST cohort. In terms of cardiopulmonary complications, α-thalassemia was associated with lower prevalence of acute chest syndrome history, oxygen desaturation, elevated TRV, and elevated NT-proBNP concentration in the Walk-PHaSST cohort, but these trends were not as clear in the PUSH cohort. In the PUSH cohort, the LV end diastolic Z score and LV mass index were higher in SCD patients without α-thalassemia while in the WalkPHaSST cohort the LV mass index was also higher in SCD patients without α-thalassemia. Table 5 depicts pulmonary function tests according to α-thalassemia genotype, with no significant differences being found.
Hemoglobin F and cardiopulmonary complications of sickle cell disease
Fetal hemoglobin levels vary over a 20-fold range in adults with SCD, and clinical observations suggest that higher levels of Hb F have beneficial effects (99, 109) , including higher hemoglobin concentrations and less hemolysis (110) (111) (112) . In one study, end organ damage seemed to be decreased in patients with Hb F levels >10% and painful crises and pulmonary complications were decreased with levels >20% (109). In the CSSCD, Hb F levels correlated inversely with the risk of painful crisis, acute chest syndrome and early mortality (10, 44, 64) . A number of genetic and non-genetic factors may influence Hb F levels in patients with SCD, including age, sex, the presence of alpha-thalassemia, genetic factors linked to the beta-globin gene locus and other genetic factors (95) . Despite the significant association between the level of Hb F and severity of disease, the predictive value of Hb F for early organ damage and death is less than perfect. While Platt et al (64) reported improved survival in patients with Hb F levels above the 75th percentile (>8.6%), this alone does not explain all the variability of SCD: many patients with Hb F levels above 8.6% do not have severe complications and early mortality, and many patients with Hb F levels above 8.6% have severe disease. Table 6 This review highlights the geographic distributions of SCD genotypes, coinheritance patterns of α-thalassemia, and varying levels of Hb F production along with influence of these factors on hemolytic parameters and pulmonary and cardiac complications of SCD. Although some of the phenotypic variation can be explained by these modifying factors, our review also emphasizes that other complex interactions including genetic modifiers need to be better understood to predict clinical severity of pulmonary disease in SCD. 
